Memantine augmentation in clozapine-refractory schizophrenia: A randomized, double-blind, placebo-controlled crossover study

S. R.T. Veerman*, P. F.J. Schulte, J D Smith, L. De Haan

*Corresponding author for this work

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. Dysfunction of neuroplasticity due to N-methyl-D-aspartate (NMDA) receptor hypofunction may be a causal factor for memory and executive dysfunctioning in schizophrenia. Deregulation of NMDA transmission in the prefrontal cortex may also explain negative and positive symptoms. Clozapine augmentation with memantine targets altered NMDA receptor-mediated neurotransmission in schizophrenia and showed substantial beneficial effects on several symptom domains in a small proof-of-concept study. We evaluate effects of memantine add-on treatment to clozapine for memory and executive function, and negative and positive symptoms in schizophrenia. Method. Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12 weeks of double-blind adjunctive treatment with memantine (n = 26) or placebo (n = 26). Crossover occurred after a 2-week placebo wash-out period. Primary endpoints were change from baseline to 12 weeks treatment and 14 weeks to 26 weeks treatment on memory and executive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-S). Side effects were assessed using the Liverpool University Neuroleptic Side-Effect Rating Scale. Results. When compared with placebo, memantine improved a composite memory score comprising verbal recognition memory and paired associates learning task scores on the CANTAB (effect size = 0.30) and PANSS negative subscale score (effect size = 0.29). Side effects were mild and transient. Conclusions. In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects. These results justify further investigations on long-term memantine augmentation to clozapine in treatment-resistant schizophrenia.

Original languageEnglish (US)
Pages (from-to)1909-1921
Number of pages13
JournalPsychological Medicine
Volume46
Issue number9
DOIs
StatePublished - Jul 1 2016

Fingerprint

Memantine
Clozapine
Cross-Over Studies
Schizophrenia
Placebos
Neuropsychological Tests
Executive Function
N-Methyl-D-Aspartate Receptors
Paired-Associate Learning
Therapeutics
Neuronal Plasticity
N-Methylaspartate
Prefrontal Cortex
Synaptic Transmission
Antipsychotic Agents

Keywords

  • Antipsychotics
  • cognitive functioning
  • memantine
  • randomized controlled trials
  • therapy-resistant schizophrenia

ASJC Scopus subject areas

  • Applied Psychology
  • Psychiatry and Mental health

Cite this

@article{055c0200d1094c9981351da82757d7fe,
title = "Memantine augmentation in clozapine-refractory schizophrenia: A randomized, double-blind, placebo-controlled crossover study",
abstract = "Background. Dysfunction of neuroplasticity due to N-methyl-D-aspartate (NMDA) receptor hypofunction may be a causal factor for memory and executive dysfunctioning in schizophrenia. Deregulation of NMDA transmission in the prefrontal cortex may also explain negative and positive symptoms. Clozapine augmentation with memantine targets altered NMDA receptor-mediated neurotransmission in schizophrenia and showed substantial beneficial effects on several symptom domains in a small proof-of-concept study. We evaluate effects of memantine add-on treatment to clozapine for memory and executive function, and negative and positive symptoms in schizophrenia. Method. Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12 weeks of double-blind adjunctive treatment with memantine (n = 26) or placebo (n = 26). Crossover occurred after a 2-week placebo wash-out period. Primary endpoints were change from baseline to 12 weeks treatment and 14 weeks to 26 weeks treatment on memory and executive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-S). Side effects were assessed using the Liverpool University Neuroleptic Side-Effect Rating Scale. Results. When compared with placebo, memantine improved a composite memory score comprising verbal recognition memory and paired associates learning task scores on the CANTAB (effect size = 0.30) and PANSS negative subscale score (effect size = 0.29). Side effects were mild and transient. Conclusions. In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects. These results justify further investigations on long-term memantine augmentation to clozapine in treatment-resistant schizophrenia.",
keywords = "Antipsychotics, cognitive functioning, memantine, randomized controlled trials, therapy-resistant schizophrenia",
author = "Veerman, {S. R.T.} and Schulte, {P. F.J.} and Smith, {J D} and {De Haan}, L.",
year = "2016",
month = "7",
day = "1",
doi = "10.1017/S0033291716000398",
language = "English (US)",
volume = "46",
pages = "1909--1921",
journal = "Psychological Medicine",
issn = "0033-2917",
publisher = "Cambridge University Press",
number = "9",

}

Memantine augmentation in clozapine-refractory schizophrenia : A randomized, double-blind, placebo-controlled crossover study. / Veerman, S. R.T.; Schulte, P. F.J.; Smith, J D; De Haan, L.

In: Psychological Medicine, Vol. 46, No. 9, 01.07.2016, p. 1909-1921.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Memantine augmentation in clozapine-refractory schizophrenia

T2 - A randomized, double-blind, placebo-controlled crossover study

AU - Veerman, S. R.T.

AU - Schulte, P. F.J.

AU - Smith, J D

AU - De Haan, L.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background. Dysfunction of neuroplasticity due to N-methyl-D-aspartate (NMDA) receptor hypofunction may be a causal factor for memory and executive dysfunctioning in schizophrenia. Deregulation of NMDA transmission in the prefrontal cortex may also explain negative and positive symptoms. Clozapine augmentation with memantine targets altered NMDA receptor-mediated neurotransmission in schizophrenia and showed substantial beneficial effects on several symptom domains in a small proof-of-concept study. We evaluate effects of memantine add-on treatment to clozapine for memory and executive function, and negative and positive symptoms in schizophrenia. Method. Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12 weeks of double-blind adjunctive treatment with memantine (n = 26) or placebo (n = 26). Crossover occurred after a 2-week placebo wash-out period. Primary endpoints were change from baseline to 12 weeks treatment and 14 weeks to 26 weeks treatment on memory and executive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-S). Side effects were assessed using the Liverpool University Neuroleptic Side-Effect Rating Scale. Results. When compared with placebo, memantine improved a composite memory score comprising verbal recognition memory and paired associates learning task scores on the CANTAB (effect size = 0.30) and PANSS negative subscale score (effect size = 0.29). Side effects were mild and transient. Conclusions. In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects. These results justify further investigations on long-term memantine augmentation to clozapine in treatment-resistant schizophrenia.

AB - Background. Dysfunction of neuroplasticity due to N-methyl-D-aspartate (NMDA) receptor hypofunction may be a causal factor for memory and executive dysfunctioning in schizophrenia. Deregulation of NMDA transmission in the prefrontal cortex may also explain negative and positive symptoms. Clozapine augmentation with memantine targets altered NMDA receptor-mediated neurotransmission in schizophrenia and showed substantial beneficial effects on several symptom domains in a small proof-of-concept study. We evaluate effects of memantine add-on treatment to clozapine for memory and executive function, and negative and positive symptoms in schizophrenia. Method. Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12 weeks of double-blind adjunctive treatment with memantine (n = 26) or placebo (n = 26). Crossover occurred after a 2-week placebo wash-out period. Primary endpoints were change from baseline to 12 weeks treatment and 14 weeks to 26 weeks treatment on memory and executive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-S). Side effects were assessed using the Liverpool University Neuroleptic Side-Effect Rating Scale. Results. When compared with placebo, memantine improved a composite memory score comprising verbal recognition memory and paired associates learning task scores on the CANTAB (effect size = 0.30) and PANSS negative subscale score (effect size = 0.29). Side effects were mild and transient. Conclusions. In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects. These results justify further investigations on long-term memantine augmentation to clozapine in treatment-resistant schizophrenia.

KW - Antipsychotics

KW - cognitive functioning

KW - memantine

KW - randomized controlled trials

KW - therapy-resistant schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84964034036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964034036&partnerID=8YFLogxK

U2 - 10.1017/S0033291716000398

DO - 10.1017/S0033291716000398

M3 - Article

C2 - 27048954

AN - SCOPUS:84964034036

VL - 46

SP - 1909

EP - 1921

JO - Psychological Medicine

JF - Psychological Medicine

SN - 0033-2917

IS - 9

ER -